Enterohemorrhagic escherichia coli: A family of emerging pathogens

Digestive Diseases

Volumn 15, Issue 1-2, 1997, Pages 67-91

  Noël, James M ^a   Boedeker, Edgar C ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Enterohemorrhagic Escherichia coli; Hemolytic uremic syndrome; Hemorrhagic colitis; Shiga like toxins; Virulence factors, attaching effacing

Indexed keywords

BACTERIAL TOXIN; CYTOTOXIN;

ANIMAL; BACTERIUM ADHERENCE; BIOSYNTHESIS; CHILD; CHRONIC KIDNEY FAILURE; CLASSIFICATION; DISEASE MODEL; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE MUCOSA; KIDNEY TRANSPLANTATION; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; REVIEW; ULCERATIVE COLITIS; VIRULENCE;

ANIMALS; BACTERIAL ADHESION; BACTERIAL TOXINS; CHILD; COLITIS, ULCERATIVE; CYTOTOXINS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INTESTINAL MUCOSA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; VIRULENCE;

EID: 0030624633     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171588     Document Type: Article

References (179)

1. Griffin PM, Ostroff SM, Tauxe RV, Greene KD, Wells JG, Lewis JH, Blake PA: Illness associated with Escherichia coli OI57:H7 Infections, A broad clinical spectrum, Ann Intern Med 1988:109:705-712.
2. Rosenweig JN, Gourlcy GR: Vero-toxic Escherichia coli in human disease, J Pediatr Gastroenterol Nutr 1991:12:295-304.
3. Rowe PC, Orrbine E, Lior H, Wells GA, McLaine PN: A prospective study of exposure to vcroloxin-pro-ducing Escherichia coli among Canadian children with haemolytic uraemic syndrome, Epidemiol Infect 1993;110:1-7.
4. Schleipcr A, Rowe PC, Orrbine E, Zouhck M, Clark W, Wolfish N, McLaine PN; Sequelae of haemolytic uraemic syndrome, Arch Dis Child 1992:67:930-934.
5. Griffin PM, Tauxe RV: The epidemiology of infections caused by Escherichia coli 0157:H7, other entc-rohemorrhagic E coli, and the associated hemolytic uremic syndrome, Epidemiol Rev 1991;13:60-98.
6. Center for Disease Control, 1993 Update: Multistatc outbreak of H: coli 0157:1-17, MMWR 1993:42:258-263.
7. Pickering LK, Obnc TG, Stapleton B: Hemolytic-uremic syndrome and cnlcrohemorrhagic Escherichia coli, Pediatr Infect Dis J 1994:13:459-476.
8. Remis RS, MacDonald KL, Riley LW, Puhr ND, Wells JG, Davis BR, Blake PA, Cohen ML: Sporadic cases of hemorrhagic colitis associated with Escherichia coli OI57:H7-Clinical, epidemiologic, and bacleriologic features, Ann Intern Med 1984:101:624-626.
9. Lopez EL, Devoto S, Fayad A, Ca-nepa C, Morroco AL, Cleary T: Association between severity of gastrointestinal prodrome and longterm prognosis in classic hemolytic-uremic syndrome, J Pediatr 1992: 120:210-215.
10. Martin DL, MacDonald KL, White KE, Soler JT, Ostcrholm MT: The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota, N Engl J Med 1990:323: 1161-1167.
11. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargett NT, Blake PA, Cohen M: Hemorrhagic colitis associated with a rare Escherichia coli serotype, N Engl J Med 1983:308:681-685.
12. Lopez EL, Diaz M, Grinstcin S, Dc-voto S, Mendilaharzu F, Murray BE, Ashkenazi S, Rubcllio E, Woloj M, Vasquez M, Turco M, Pickering LK, Cleary' TG: Hemolytic uremic syndrome and diarrhea in Argentine children: The role of Shiga toxin, J Infect Dis 1989:160:469-475.
13. Crabbe DCG, Broklebank JT, Spicer RD: Gastrointestinal complications of the hemolytic uremic syndrome, J R Soc Med 1990:83:773-775.
14. MacDonald KL, O'Leary MJ, Cohen ML, Norris P, Wells JG, Noll E, Kobayashi JM, Blake PA: Escherichia coli 0157:H7, an emerging gastrointestinal pathogen, Results of a one-vear, prospective, population-based study, JAMA 1988:259:3567-3570.
15. Pavia AT, Nichols CR, Green DP, Tauxe RV, Motticc S, Greene KD, Wells JG, Siegler RL, Brewer ED, Hannon D, Blake PA: Hemolytic-uremic syndrome during an outbrek of Escherichia coli 0157:H7, Infections in institutions for mentally retarded persons: Clinical and epidemiologic observations, J Pediatr 1990:116:544-551.
16. Hamano S, Nakanishi Y, Nara T, Seki T, Ohtani T, Oishi T, Joh K, Oikawa T, Muranatsu Y, Ogawa Y, Ahasi S: Neurologic manifestations of hemorrhagic colitis in the outbreak of Escherichia coli OI57:H7 infection in Japan, Acta Paediatr 1993;82:454-458.
17. Rowe PC, Orrbine E, Wells GA, McLaine PN, CPKDRC: Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988, J Pediatr 1991:119: 218-224.
18. Robson WLM, Leung AKC, Miller-Hughes DJ: Recurrent hemorrhagic colitis caused by Escherichia coli 0157:117, Pediatr Infect Dis J 1993: 12:699-701.
19. Siegler RL, Griffin PM, Barrett TJ, Slrockbine NA: Recurrent hemolytic uremic syndrome secondary' to Escherichia co/iO 157:117 infection, Pediatrics 1993:81:666-668.
20. Karmali M, Petrie M, Lint C, Fleming PC, Arbus GS, Lior H: The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli, J Infect Dis 1985:151:775-789.
21. Kaplan BS, McGowan KL: Hemolytic uremic syndrome, Curr Opin Infect Dis 1994:7:351-357.
22. Lior II, Rowe PC, Orrbine E, Wells GA, McLaine PN, CPKDRC: Microbiology of hemolytic uremic syndrome in Canada, Second International Symposium on Verocvtotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, P1.21.
23. Pavia AT, Siegler RL, Christoffen R, Milligan M: A 20-ycar population-based study of hemolytic uremic syndrome: Evidence for the importance of SLT-producing E coli, Second International Symposium on Verocvtotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, AOLL
24. Caprioli A, Luzzi I, Rosmini F, Resti C, Edefonti A, Perfumo F, Farina C, Goglio A, Gianviti A, Riz-zoni G: Communitvwide outbreak of hemolytic-uremic syndrome associated with non-0157 verocytotox-in-producing Escherichia coli, J Infect Dis 1994:169:208-211.
25. OstrofT SM, Kobayashi JM, Lewis JH: Infections with Escherichia coli 0157:117 in Washington State, JAMA 1989:262:355-359.
26. Carter AD, Borczyk AA, Carlson JAK, Harvcv B, Hockin JL, Karmali MA, Krishnan C, Korn DA, Lior H: A severe outbreak of Escherichia coli 0157:H7-associated hemorrhagic colitis in a nursing home, N Engl J Med 1987:317:1496-1500.
27. Cimolai N, Carter IE, Morrison BJ, Anderson JD: Risk Caclors for the progression of Escherichia coli 0157:117 enteritis to hemolytic-uremic syndrome, J Pediatr 1990:116: 589-592.
28. Beutin L, Aleksic S, Zimmerman S, Gleier K: Virulence factors and phenotypic traits of verotoxigenic strains of Escherichia coli isolated from human patients in Germany, Med Microbiol Immunol (Belg) 1994;183:13-21.
29. Marsh J, MacLeod AF: A restaurant-associated outbreak of E, coli 0157 infection, J Public Health Med 1992:14:78-83.
30. Spika JS, Parsons JE: HUS anddiar-rhoca associated with E, coli 0157 in a day care, J Pcdiatr 1986:109:287-291.
31. Besser RE, Lett SM, Weber JT, Dovlc MP, Barrett TJ, Wells JG, Griffin PM: An outbreak of diarrhea and HUS from E, coli OI57:H7 in fresh pressed apple cider, JAMA 1993:269:2217-2220.
32. Brewster DH, Brown MJ: An outbreak of E, coli 0157 associated with a children's paddling pool, Epidemiol Infect 1994:112:441-447.
33. Giannella RA, Brotman M, Alm PF, Bauman H, Bennett AR, Black RF, Bruhn CM, Cohen MB, Gorbach SL, Kaper JB, Roberts MR, Staneck JL, Taylor S, Troutl HF: AGA Consensus Statement E, coli 0157:H7 Infections: An Emerging National Health Crisis, AGA Foundation Meeting, Washington, July 1994.
34. Karmali MA, Arbus G, Petrie M, Patrick ML, Roscoc M, Shaw J, Lior H: Hospital-acquired Escherichia ro//OI57:H7 associated hacmolytic uraemic syndrome in a nurse (letter), Lancet 1988;i:526.
35. Belongia EA, Ostcrholm MT, Soler JT, Ammend DH, Brown IE, MacDonald KL: Transmission of Escherichia coli 0157:H7 infection in Minnesota day-care facilities, JAMA 1993;269:883-888.
36. Rowe PC, Orrbine E, Lior H, Wells GA, McLaine PN, CPKDRC: Diarrhoea in close contacts as a risk factor for childhood hacmolytic uraemic syndrome, Epidemiol Infect 1993;10:9-16.
37. Caprioli A, Luzzi I, Rosmini F, Resti C, Edefonti A, Perfumo F, Farina C, Goglio A, Gianviti A, Rizzoni G: Communitywide outbreak of hemolytic-uremic syndrome associated with Non-0157 verocyloloxin-pro-ducing Escherichia coli, J Infect Dis 1994:169:208-211.
38. Rowe PC, Orrbine E, Ozborn M, Wells GA, Winter W, Lior H, Manuel D, Mulaine PN: Epidemic Escherichia coli 0157: H 7 gastroenteritis in a Canadian Inuit community: Intestinal illness in family members as a risk factor, J Pcdiatr 1994:124: 21-26.
39. Renwick SA, Wilson JB, Clarke RC, Lior H, Borczyk HA, Spika J, Rahn K, McFaddcn K, Brouwer A, Copps A, Anderson NG, Alves D, Karmali MA: Evidence of direct transmission of Escherichia coli 0157 H7 infection between calves and a human, J Infect Dis 1993:168:792-793.
40. Bitzan M, Ludwig K, Klemt M, König H, Büren J, Müller-Wiefel DE: The role of Escherichia coh 0157 infections in the classical (entcro-pathic) hacmolytic ureamie syndrome: Results of a Central European, multicenter study, Epidemiol Infect 1993:110:183-196.
41. Kaplan BS, McGowan KL: Hemolytic uremic syndrome, Curr Opin Infect Dis 1994:7:351-357.
42. MacDonald KL, Osterholm MT: The emergence of Escherichia coli OI57:H7 infection in the United States, JAMA 1993:269:2264-2266.
43. Bégué RE, Neill MA, Papa EF, Den-nehy PH: A prospective study of Shiga-like toxin-associated diarrhea in a pediatric population, J Pcdiatr Gastroenterol Nutr 1994:19:164-169.
44. Tarr PI: '4* normal flora' (Or is it?), J Pediatr Gastroenterol Nutr 1994; 19:145-147.
45. Park CH, Hixon DL, Morrison WL, Cook CB: Rapid diagnosis of enlerohcmorrhagic Escherichia coli 0157:H7 directly from fecal specimens using immunofluorescence stain, Am J Clin Pathol 1994:101: 91-94.
46. Ostrot TSM, Tarr PL Neill MA, Lewis JH, Hargrctt-Bcan N, Kobayashi JM: Toxin genotypes and plasmid profiles as determinants of systemic sequelae in E, coli OI57:H7 infection, J Infect Dis 1989:160: 994-998.
47. Rowe PC, Orrbine E, Wells GA, Lior H, McLaine PN, CPKDRC: Risk of hemolytic uremic syndrome after E, coli 0157:H7 infection, Second International Symposium on Verocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, PL3.
48. Siegler RL: Management of hemolytic-uremic syndrome, J Pediatr 1988:112:1014-1019.
49. Pai CH, Ahmed N, Lior H: Epidemiology of sporadic diarrhea due to verotoxin-producing E coli: A two-year prospective study, J Infect Dis 1988:157:1054-1057.
50. Karmali VIA: Infection by verocyto-toxin-producing Escherichia coli, Clin Microbiol Rev 1989;2:15-38.
51. Caprioli A, Luzzi I, Rosmini F, Re-sti C, Edefonli A, Perfumo F, Farina C, Goglio A, Gianviti A, Rizzoni G: Communitywide outbreak of hemolytic-uremic syndrome associated with non-0157 vcrocvtotoxin-pro-ducing Escherichia coh, J Infect Dis 1994:169:208-211.
52. Campos LC, Whittam TS, Gomes TAT, Andrade JRC, Trabulsi LR: Escherichia coli scrogroup 0111 includes several clones of diarrheagen-ic strains with different virulence properties, Infect Immun 1994:62: 3282-3288.
53. Mariani-Kurkdjian P, Dcnamur E, Milon A, Picard B, Cave H, Lam-bert-Zechovsky N, Loirat C, Goullct P, Sansonelti PJ, Elion J: Identification of a clone of Escherichia coli O103-H2 as a potential agent of hemolvtic-uremic syndrome in France, J Clin Microbiol 1993:31: 296-301.
54. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO: Escherichia coli OI57:H7 and the hemolytic-uremic syndrome: Importance of early cultures in establishing the etiology, J Infect Dis 1990:162:553-556.
55. Cordovcz A, Prado V, Maggi L, Cordero J, Martinez J, Misraji A, Rios R, Soza G, Ojeda A, Levine MM: Enterohemorrhagic Escherichia coti associated with hemolytic-uremic syndrome in Chilean children, J Clin Microbiol 1992;30:2153-2157.
56. Gunzer F, Bdhm H, Riissman H, Bitzan M, Aleksic S, Karch H: Molecular detection of sorbitol-fermenting Escherichia coti 0157 in patients with hemolvlic-urcmic syndrome, J Clin Microbiol 1992:30: 1807-1810.
57. Luzzi I, Minelli F, Gianviti A, Carpioli A: Impaired detection of faecal verocvtotoxin in the presence of Clostridium difficile cvtotoxin in patients with haemolytic-uremic syndrome, Eur J Clin Microbiol Infect Dis 1992:11:934-936.
58. Karch H, Slrockbine NA, O’brien AD: Growth of Escherichia coli in the presence of trimcthoprim-sulfa-methoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay, FEMS Microbiol Lett 1986:35:141-145.
59. Law D, Hamour AA, Achcson DWK, Panigrahi H, Ganguli LA, Denning DW: Diagnosis of infections with Shiga-like toxin-producing Escherichia coti by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples, J Med Microbiol 1994:40:241-245.
60. Johnson RP, MacDonald LA, Johnson ST, Samuel JE, Turcovski S: Rapid detection of vcrocytotoxins by a rcceptor-based enzyme-linked immunosorbent assay, Second International Symposium on Verocv-totoxm (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, J une 1994, AO 1.6.
61. Burke D, Jumaili A, Mardini A, Record CO: Culture-negative cyto-toxin-positive stools in community-acquired diarrhoea, Gut 1993:34: 192-193.
62. Krishnan C, Fitzgerald VA, Dakin SJ, Behmc RJ: Laboratory investigation of outbreak of hemorrhagic colitis caused by Escherichia coli Ol 57:117, J Clin Microbiol 1987;25: 1043-1047.
63. Newland JW, Neil RJ: DNA probes for Shiga-like toxins I and II for toxin-converting bacteriophages, J Clin Microbiol 1988:26:1292-1297.
64. Begaud E, Jourand P, Morillon M, Mondct D, Germani Y: Detection of diarrhcogcnic Escherichia coli in children less than ten years old with and without diarrhea in New Caledonia using seven acctylaminofluor-enc-labeled DNA probes, Am J Trop Med Hyg 1993:48:26-34.
65. Brian MJ, Frosolono M, Murray BE, Miranda A, Lopez EL, Gomez I IF, Cleary TG: Polymerase chain reaction for diagnosis of cntcrohemor-rhagic Escherichia coli infection and hemolytic-uremic syndrome, J Clin Microbiol 1992:30:1801-1806.
66. Paton AW, Paton JC, Goldwater PN, Manning PA: Direct detection of Escherichia coli Shiga-like toxin genes in primary fecal cultures by polymerase chain reaction, J Clin Microbiol 1993:31:3063-3067.
67. Pollard DR, Johnson WM, Lior H, Taylor SD, Rozee KR: Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction, J Clin Microbiol 1990:28:540-545.
68. Begum D, Slrockbine NA, Sowers EG, Jackson MP: Evaluation of a technique for identification of Shiga-like toxin-producing Escherichia coli by using polymerase chain reaction and digoxigenin-labcled probes, J Clin Microbiol 1993:31:3153-3156.
69. Bitzan M, Karch H: Indirect hemagglutination assay for diagnosis of Escherichia coli 0157 infec'.ion in patients with hemolytic-uremic syndrome, J Clin Microbiol 1992:30: 1174-1178.
70. Stuart FA, Corbel MJ: Identification of a serological cross-reaction between Brucella ahorias and Escherichia coli 0157, Vet Rec 1982: 110:202-203.
71. Elliott E, Li Z, Stiel D, Buret A, Wallace J, Brzuszczak I, O’loughlin E: Modulation of host response to Escherichia coli 0157:H7 infection by anti-CD 18 antibody in rabbits, Gastroenterology 1994:106:1554-1561.
72. O’brien AD, Melton AR, Schmitt CK, McKee ML, Batts ML, Griffin DE: Profile of Escherichia coli 0157:117 pathogen responsible for hamburger-borne outbreak of hemorrhagic colitis and hemolytic uremic syndrome in Washington, J Clin Microbiol 1993:31:2799-280.
73. McDaniel TK, Jarvis KG, Donnen-berg MS, Kaper JB: A genetic locus of enicrocvtc effacement conserved among diverse enterobacterial pathogens, Proc Natl Acad Sci USA 1995:92:1664-1668.
74. O’brien AD, Mellon AR, Schmitt CK, McKee ML, Batts ML, Griffin DE: Profile of Escherichia coli 0157:117 pathogen responsible for hamburger-borne outbreak of hemorrhagic colitis and hemolytic uremic syndrome in Washington, J Clin Microbiol 1993:31:2799-2801.
75. Donnenberg MS, Kaper JB: Enlero-pathogcnic Escherichia coli: Minireview, Infect Immun 1992:60:3953-3961.
76. Karch H, Uccscmann J, Laufs R, O’brien AD, Tacket CO, Lcvine MM: A plasmid of enterohemorrhagic Escherichia coli 0157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells, Infect Immun 1987: 55:455-461.
77. Fratamico PM, Bhaduri S, Buchanan RL: Studies on Escherichia coli serotype 0157:117 strains containing a 60-MDa plasmid and on 60-MDa plasmid-cured derivatives, J Med Microbiol 1993:39:371-381.
78. Tzipori S, Karch H, Wachsmuth KI, Robins-Brownc RM, O’brien AD, Lior H, Cohen ML, Smithers J, Levine MM: Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic E, coli 0157:H7 in gnotobiotic piglets, Infect Immun 1987:55:3117-3125.
79. Sjogren R, Neill R, Rachmilcwitz D, Fritz D, Newland J, Sharpnack D, Colleton C, Fondacaro J, Gemski P, Boedeker E: Role of Shiga-like toxin I in bacterial enteritis: Comparison between isogeneic Escherichia coli strains induced in rabbits, Gastroenterology 1994:106:306-317.
80. Donncnbcrg MS, Yu J, Kaper JB: A second chromosomal gene necessary for intimate attachment of entero-palhogenic Escherichia coli to epithelial cells, J Bacteriol 1993:175: 4670-4680.
81. Dytoc MT, tsmaili A, Philpott DJ, Soni R, Brunlon JL, Sherman PM: Distinct binding properties of iY/ft-1-ncgative veroeytotoxin producing Escherichia coli of serotype Ol 13:H21, Infect Immun 1994:62: 3494-3505.
82. Foubistcr V, Roscnshine I, Donnen-berg MS, Finlay BB: The eaeB gene of enteropathogenic Escherichia coli is necessary for signal transduction in epithelial cells, Infect Inimun 1994:62:3038-3040.
83. Louie M, de Azavedo JCS, Handals-man MYC, Clarke CG, Ally B, Dytoc M, Sherman P, Brunton J: Expression and characterization of the eaeA gene product of Escherichia coli serotype OI57:H7, Infect Immun 1993:61:4085-4092.
84. Jarvis KG, Giron JA, Jerse AE, McDaniel TK, Donnenberg MS, Kaper JB: Enteropathogenic Escherichia coli contains a specialized secretion system necessary for the export of proteins involved in attaching and effacing lesion formation, Proc Natl Acad Sci USA 1995:92: 7996-8000.
85. O'Brien AD, Tesh VL: Adherence and colonization mechanisms of en-teropathogcnic and enterohemorrhagic Escherichia coli, Microb Pa-thog 1992;12:245-254.
86. Jerse AE, Yu J, Tall BD, Kaper JB: A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells, Proc Natl Acad Sci USA 1990:87:7839-7843.
87. Louie M, de Azavedo JCS, Handals-ntan MYC, Clarke CG, Ally B, Dytoc M, Sherman P, Brunton J: Expression and characterization of the eaeA gene product of Escherichia coli serotype OI57:H7, Infect Immun 1993;61:4085-4092.
88. Becbakhee G, Louie M, de Azavedo JCS, Brunton J: Cloning and nucleotide sequence of the eaeA gene ho-mologue from Escherichia coli serotype OI57.H7, FEMS Microbiol Lett 1992:9:63-68.
89. Gomez-Duate OG, Kaper JB: A plasmid-encoded regulatory region activates chromosomes eaeA expression in enteropathogenic Escherichia coli, Infect Immun 1995: 63:1767-1776.
90. Donnenberg MS, Tacket CO, Los-onsky G, Nataro JP, Kaper JB, Levine MM: The role of the eae gene in experimental human cnleropatho-genic Escherichia coli infection, J Clin Invest 1993:92:1412-1417.
91. Sherman P, Cockerill F, Soni R, Brunton J: Outer membranes are competitive inhibitors of Escherichia coli 0157:117 adherence to epithelial cells, Infect Immun 1991:59: 840-899.
92. Knutton S, Baldwin T, Williams PH, McNeish AS: Actin accumulation at sites of bacterial adhesion to tissue culture cells: Basis of a new diagnostic test for enteropathogenic and entcrohemorrhagic Escherichia coli, Infect Immun 1989:57:1290-1298.
93. Louie M, de Azavcdo J, Clarke R, Borczyk A, Lior H, Richter M, Brunton J: Sequence heterogeneity of the eae gene and detection of verotoxin-producing Escherichia coli using serolvpe-spccific primers, Epidemiol Infect 1994; 112:449-461.
94. Dytoc M, Fedorko L, Sherman PM: Signal transduction in human epithelial cells infected with attaching and effacing Escherichia coli in vitro, Gastroenterology 1994:106: 1150-1161.
95. Li Z, Bell C, Buret A, Robins-Browne R, Stiel D, O’Loughlin E: The effect of enterohemorrhagic Escherichia coli OI57:H7 on intestinal structure and solute transport in rabbits, Gastroenterology 1993:104: 467-474.
96. Fontaine A, Arondcl J, Sansoneti PJ: RoleofShiga toxin in the pathogenesis of bacillarv dysentery, studied by usinga Toxmutant of Shigella dysenteriae, I, Infect Immun 1988; 56:3099-3109.
97. O’brien AD, Holmes RK: Shiga and Shiga-like toxins, Microbiol Rev 1987:51:206-220.
98. Tesh VL, O’brien AD: The pathogenic mechanisms of Shiga toxin and Shiga-like toxins, Mol Microbiol 1991:5:1817-1822.
99. Conradi H: Über lösliche, durch aseptische Autolvse erhaltene Giftstoffe von Ruhr-und Tvphcsbazil-len, Dt sch Med Wochenschr 1903: 29:26-28.
100. Lasfarqucs E, Delaunay A: Cultures de tissus appliquées à la solution de problèmes immunologi-qucs, I, Etude du pouvoir nécrosant de toxines microbiennes in vitro, Ann Inst Pasteur (Paris) 1946: 72:39-43.
101. Bridgewater FAJ, Morgan RS, Rowson KEK, Wright GP: The neurotoxin of Shigella sliigae Morphological and functional lesions produced in the central nervous system of rabbits, Br J Exp Pathol 1995;36:447-453.
102. Keusch GT, Grady GF, Mata U, Mclver J: The pathogenesis of.'Shigella diarrhea, I, Enterotoxin production by Shigella dysenteria I, J Clin Invest 1972:51:1212-1218.
103. Sandvig K, van Deurs B: Toxin-induced cell Ivsis: Protection by 3-methyladcnine and cyclohexint-ide, Êxp Cell Res 1992:200:253-262.
104. Saxena SK, O’brien AD, Ackerman EJ: Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidascs of 28S RNA when microinjected into Xenopus oocytes, J Biol Chem 1989:264:596-601.
105. Cantcy JR: Shiga toxin-An expanding role in the pathogenesis of infectious diseases, J Infect Dis 1985:151:766-779.
106. Konawalchuk J, Speirs JI, Stavric S: Vero response to a cvtotoxin of E, coli, Infect Immun 1977; 18: 775-779.
107. Strockbine NA, Marques LRM, Holmes RK, O’brien AD: Two toxin-converting phages from Escherichia coli 0157:H7 strain 933 encode antigenically distinct toxins with similar biological activities, Infect Immun 1986:53: 135-140.
108. O'Brien AD, Karmali MA, Scotland SM: A proposal for rationalizing the nomenclature of the Escherichia coli cytoloxins, Second International Symposium on Ve-rocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, A02.8.
109. Tcsh VL, Burris JA, Owens JW, Gordon VM, Waldolkowski EA, O'Brien AD, Samuel JE: Comparison of ihe relative toxicities of Shi-ga-likc toxins type I and type II for mice, Infect Immun 1993:61: 3392-3402.
110. Yamasaki S, Fufrutani M, Ito K, Igaraski K, Nishibuchi M, Takida Y: Importance of arginine at position 170 of the A-subunit of Vero toxin 1 produced by cntcrohemor-rhagic Escherichia coli for toxin activity, Microb Pathog 1991:11:1-9.
111. Burgess BJ, Roberts LM: Proteolytic cleavage at arginine residues within the hydrophilic disulfide loop of Escherichia coli Shiga-like toxin I A subunit is not essential for cytotoxicity, Mol Microbiol 1993:10:171-179.
112. Austin PR, Jablonski PE, Bohach GA, Dunker AK, Hovde CJ: Evidence that the A; fragment of Shi-ga-like toxin type I is required for holotoxin integrity, Infect Immun 1994;62:1768-1775.
113. Ohmura M, Cao C, Karasawa T, Okuda J, Kurazono H, Gannon VPJ, Gyles CL, Takeda Y: Purification and some properties of Vero toxin 2 (Shiga-like toxin II) variant (SLT-IKj) of Escherichia coli isolated from infectant diarrhea, Microb Pathog 1993:15:399-405.
114. Kiissman H, Schmidt I I, Caprioli A, Karch H: Highly conserved B-subunit genes of Shiga-like toxin II variants found in Escherichia coli 0157:117 strains, FEMS Microbiol Lett 1994:118:335-340.
115. Rhine AA, Lingwood CA: Capping and receptor-mediated cndocyto-sis of cell-bound vcroloxin (Shiga-like toxin) 1: Chemical identification of an amino acid in the B-sub-unit necessary for efficient receptor glycolipid binding and cellular internalization, J Cell Physiol 1994:161:319-332.
116. MacLeod DL, Gyles CL: Purification and characterization of an Escherichia coli Shiga-like toxin II variant, Infect Immun 1990:58: 1232-1239.
117. Bitzan M, Richardson S, Huang C, Boyd B, Petrie M, Karmali MA: Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro, Infect Immun 1994:62:3337-3347.
118. Pudymaitis A, Armstrong G, Ling-wood CA: Verotoxin-resistant cell clones are deficient in glycolipid globotriosylceramide: Differential basis for phenotype, Arch Biochem Biophys 1991;286:448-452.
119. Lingwood CA, Law H, Richardson S, Petrie M, Brunton JC, DeGran-dis S, Karmali M: Glycolipid binding of purified and recombinant Escherichia coli produced verotox-in in vitro, J Biol Chem 1987:262: 8834-8839.
120. Jacewiez MS, Mobassalch M, Gross SR, Balasubrantanian KA, Daniel PF, Raghavan S, McClcur RH, Keusch GT: Pathogenesis of Shigella diarrhea, A mammalian cell membrane glycolipid Gb*, is required but not sufficient to confer sensitivity to Shiga toxin, J Infect Dis 1994:169:538-546.
121. Lingwood CA, Yiu SK: Glycolipid modification ofai-intcrferon binding, Biochem J 1992:283:25-26.
122. Van Settcn PA, Verslratcn HGG, van den Heuvel LPWJ, Karmali MA, Monnens LAH: Human monocytes produce cytokines in response to verotoxin-1 binding, Binding characteristics and analysis of cytokine production, Second International Symposium on Ve-rocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, A02.3.
123. Tcsh VL, Ramcgowda B, Samuel JE: Purified Shiga-like toxins induce expression ofproinllarimato-ry cytokines from murine peritoneal macrophages, Infect Immun 1994:62:5085-5094.
124. Van dc Kar NCAJ, Monnens LAH, Karmali MA, van Hins-bergh VWM: Tumor necrosis factor and interleukin-1 induce expression of the vcrocytotoxin receptor globotriaoxylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome, Blood 1992:80:2755-2764.
125. Maloney MD, Lingwood CA: CD 19 has a potential CD77 glo-botriaoxylceramidcFbinding site with sequence similarity to vcro-toxin B-subunits: Implications of molecular mimicry for B cell adhesion and entcrohcmorrhagic Escherichia coli pathogenesis, J Exp Med 1994:180:191-201.
126. Johnson SM: The effect of interfer-on-alpha on the ccto 5-nucleoti-dasc of human Ivmphoblastoid B-cell lines depends on the class of immunoglobulin secreted, Immunology 1991;74:44-49.
127. Kiarash A, Boyd B, Lingwood CA: Glycosphingolipid receptor function is modified by laity acid content, J Biol Chem 1994:269: 11138-11146.
128. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, lgarashi K: Site of action of a Vero toxin (VT2) from Escherichia coli 0157.H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-gly-cosidase activity of the toxins, Eur J Biochem 1988:171:45-50.
129. Obrig T, Moran T, Brown J: The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis, Biochem J 1987: 244:287-294.
130. Kaye SA, Louise CB, Bovd B, Lingwood A, Obrig T: Shiga toxin-associated hemolytic uremic syndrome: Interleukin-1 i enhancement of Shiga cytotoxicity toward human vascular endothelial cells in vitro, Infect Immun !993;6I: 3886-3891.
131. Barrett TJ, Potter ME, Stroekbine NA: Evidence for participation of the macrophage in Shiga-like toxin ll-induced lethality in mice, Microb Pathog 1990:9:95-103.
132. Richardson SE, Karmali MA, Becker LE, Smith CR: The histo-pathology of the hemolytic uremic syndrome associated with verotox-m-produeing Escherichia coli infections, Hum Pathol 1988:19: 1102-1108.
133. Chart H, Law D, Rowe B, Achcson DWK: Patients with haemolytic uraemic syndrome caused by Escherichia coli 0157: Absence of antibodies to verocytotoxin VTI or VT2, J Clin Pathol 1993:46:1053-1054.
134. Voelker R: New strategies aimed at E coli0157-.H7, JAMA 1994:272: 503.
135. Wallcrspicl JN, Ashkenazi S, Morrow AL, Cleary TG: Effect of sub-inhibitory concentrations of antibiotics on extracellular Shiga-like toxin I, Infection 1992:20:25-29.
136. Burgner DP, Rfidah H, BeattieTJ, Seal DV: Clostridium difficile alter hemolytic uremic syndrome, Arch Dis Cliild 1993:69:239-240.
137. Dupont HL, Harich RB: Adverse effect of Lomotil therapy in shigellosis, JAMA 1973:226:1525-1528.
138. Proulx F, Turgeon JP, Delagc G, Laficur L, C'hicoinc L: Randomized, controlled trial of antibiotic therapy for Escherichia coli Ol 57-.H7 enteritis, J Pcdiatr 1992: 121:299-303.
139. Armstrong GD, Rowe PC, Orrbine E, Goodyear P, Wells GA, Lior H, Klassen T, MacKcnzic A, Auclair F, Rafter DJ, McLainc PN: Results of a phase 1 study into the use of Synsorb-Pk for preventing hemolytic uremic syndrome, Second International Symposium on Verocytotoxin (Shiga-Like Toxin) Producing Escherichia coli infection, Bergamo, Italy, June 1994, A04.8.
140. Boyd B, Richardson S, Garicpv J: Serologic response to the B-sub-unit of Shiga-like toxin 1 and its peptide fragments indicate that the B-subunit is a vaccine candidate to counter the action of toxin, Infect Immun 1991;59:750-757.
141. Mullett C, Bolls C, Acheson D. Fleming E, Tseng L, Boedeker E: Serum and mucosal immune response to Shiga-like toxin I B-sub-unit during infection of adult rabbits with Escherichia coli strain RDEC-H19A: A rabbit model for enterohemorrhagic colitis, Gastroenterology 1993:104: A750.
142. Noel JM, Mullett C, Acheson D. Lowell G, Tseng L, Fleming E. Boedeker E, Latimer J: Parenteral immunization with Shiga-like toxin B subunit in proteosomes protects in a model of cntcrohcmor-rhagic E, coli colitis, J Pcdiatr Gastroenterol Nutr 1994:19:A89.
143. Noel JM, Wolf MK, McQueen C, Tseng LY, Fleming E, Pineiro-Car-rero V, Boedeker E: Protection against enterohemorrhagic E coli colitis in a rabbit model by previous infection with an iscgcncic bacteria lacking Shiga-like toxin-1, Gastroenterology 1995; 108:A885.
144. Cimolai N, Morrison BJ, Carter JE: Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome, Pediatrics 1992: 90:616-621.
145. Keiles A, Van Dvck M, Proesmans W: Childhood haemolytic uraemic syndrome: Long-term outcome and prognostic features, Eur J Pe-diatr 1994:153:38-42.
146. Siegler RL, Davia AT, ChristolTer-son RD, Milligan MK: A 20-year population-based study of post-diarrheal hemolytic uremic syndrome in Utah, Pediatrics 1994: 94:35-40.
147. Caprioli A, Luzzi I, Romini F, Pasquini P, Cirrincionc-Alessandra G, Matteucci MC, Rizzoni G, HUS Italian Study Group: Hemolytic-uremic syndrome and Veto cyto-loxin-producing Escherichia coli infection in Italy, J Infect Dis 1992:166:154-158.
148. Riissman H, Schmidt H, Hccsc-mann J, Caprioli A, Karch H: Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli0157 strains from patients with haemolytic uraemic syndrome, J Med Microbiol 1994; 40:338-343.
149. Tarr PL Neill MA: The increasing incidence of the hemolytic-uremic syndrome in King County Washington, Am J Epidemiol 1989:129: 582-586.
150. Newburg DS, Chaturvedi P, Lopez EL, Devoto S, Fayad A, Cleary TG: Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns, J Infect Dis 1993:168:476-479.
151. Thompson PD, Meyers KEC, Nortman PJ, Tolmay FS: Is blood group Pa significant protective factor in explaining why haemolytic uraemic syndrome is less common in Black African children, Pc-diatr Nephrol 1992:6:062.
152. Louise CB, Obrig TG: Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopoly-saccharide (endotoxin) on human vascular endothelial cells in vitro, Infect Immun 1992:60:1536-1543.
153. Takeda T, Dohi S, Igarishi T, Ya-manaka T, Yoshiya K, Kobayashi N: Impairment by vcrotoxin of tubular function contributes to the renal damage seen in haemolytic uraemic syndrome, J Infect Dis 1993;27:339-341.
154. Siegler ILL, Smith JB, Lynch MB, Mohammad SF: In vitro prostacyclin production in the hemolytic-uremic syndrome, West J Med 1986;144:165-168.
155. Van de Kar NCAJ, van Hinsbergh VWM, Brommcr EJP, Monnens LAH: The fibrinolytic system in the hemolytic uremic syndrome: In vivo and in vitro studies, Second International Symposium on Verocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, A04.3.
156. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM: lnterleukin-8 and polymorphoneu-trophil leukocyte activation in hemolytic uremic syndrome of childhood, Kidney Int 1992:42:951-956.
157. Van de Kar NACJ, Sauerwein R, Demaker P, van Hinsbergh VWM, Monnens LAH: Plasma cytokine levels in the hemolytic uremic syndrome, Second International Symposium on Verocytotoxin (Shiga-LikcToxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, AP4.13.
158. Karpman D, Atidrcasson A, Thy-sell H, Kaplan B, Svanborg C: Serum and urinary cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, Second International Symposium on Verocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, AP4.5.
159. Rohan DH, Padilla EL, Sicgler RL: Endothclin concentrations and ET stimulating activity in the plasma of children with postdiarrhea IIUS, Second International Symposium on Vcrocytotoxin (Shiga-Like Toxin) Producing Escherichia coli Infection, Bergamo, Italy, June 1994, AP4.9.
160. Sicgler RE, Edwin SS, Mitchell MD: Endothclin in the urine of children with the hemolytic uremic syndrome, Pediatrics 1991:88: 1063-1066.
161. Brichard B, Vcrmvlin C, Herc-mans MT, Ninanc J, Cornu G: Plasma infusion as treatment for 33 children with haemolytic uraemic syndrome: A good therapy? Acta Clin Belg 1993:48:156-163.
162. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fcrmanian J: Treatment of the childhood haemolytic uraemic syndrome with plasma: A multicentre randomized control trial, Pediatr Nephrol 1988:2:279-285.
163. Taylor CM, Lote CJ: Prostacyclin in diarrhoea-associated haemolytic uraemic syndrome, Pediatr Nephrol 1993:7:515-519.
164. Powell UR, McC'redic DA, Taylor CM: Vitamin E treatment of haemolytic uraemic syndrome, Arch Dis Child 1984:59:401-404.
165. Robson WLM, Leung ARC: The successful treatment of atypical hemolytic uremic syndrome with plasmapheresis, Clin Nephrol 1991:35:119-122.
166. Parida SR, Milford DV, Taylor CM: Pilot study of Epoprostenol (PGL) treatment in diarrhoea-associated haemolytic uraemic syndrome, Pediatr Nephrol 1991:5: C3L
167. Rizzoni G, Claris-Appiani A, Edc-fonti A, Facchin P, Franchini F, Gusmano R, Imbasciati E, Pava-ncllo L, Pcrfumo F, Rcmuzzi G: Plasma infusion for hemolytic-uremic syndrome in children: Results of a multiccntcr controlled trial, J Pediatr 1988:112:284-290.
168. Bergstein JM, Riley M, Bang NU: Role of plasminogen activator inhibitor type I in the pathogenesis and outcome of the hemolytic uremic syndrome, N Engl J Med 1992:327:755-759.
169. Rruez W, Linde R, Becker S, Sci-fried E: Successful treatment of haemolytic uraemic syndrome with recombinant tissue-type plasminogen activator, Lancet 1993; 341:1665-1666.
170. Bcrgstcin JM: Tissue plasminogen activator therapy of glomerular thrombi in the Schwartzman reaction, Ridneylm 1989:35:14-18.
171. Vitacco M, Avalos JS, Giananto-nio G: Heparin therapy in the hemolytic uremic syndrome, J Pediatr 1974:84:345-349.
172. Arenson EB Jr., August CS: Preliminary report: Treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole, J Pediatr 1975:86:957-961.
173. O’reagan S, Chesney RW, Mon-geau JG, Robilaille P: Aspirin and dipyridamole therapy in the hemolytic uremic syndrome, J Pediatr 1980:97:173-176.
174. Powell HR, Ekert H: Streptokinase and anti-thrombotic therapy in the hemolytic-uremic syndrome, J Pediatr 1974:84:345-349.
175. Diekmann L: Treatment of the hemolytic-uremic syndrome with streptokinase and heparin, Klin Pädiatr 1980:192:430-435.
176. Jones RWA, Morris MC, Maiscy MN, Saxton I IM, Chantlcr C: Endartcrial urokinase in childhood hemolytic uremic syndrome, Kidney Int 1981;20:723-727.
177. Robson WLM, Fick GIL Jadavji T, Leung ARC: The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome, Pediatr Nephrol 1991; 5:289-292.
178. McGraw ME, Lendon M, Stevens RF, Postlethwaite R.L Taylor CM: Haemolytic uraemic syndrome and the Thomsen-Friedenreich antigen, Pediatr Nephrol 1989:3: 135-139.
179. Bitzen M, Klemt M, StelTcns R, Müller-Wiefel DE: Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls, Infection 1993:21:140-145.